CA2592991A1 - Nanoparticles for protein drug delivery - Google Patents
Nanoparticles for protein drug delivery Download PDFInfo
- Publication number
- CA2592991A1 CA2592991A1 CA002592991A CA2592991A CA2592991A1 CA 2592991 A1 CA2592991 A1 CA 2592991A1 CA 002592991 A CA002592991 A CA 002592991A CA 2592991 A CA2592991 A CA 2592991A CA 2592991 A1 CA2592991 A1 CA 2592991A1
- Authority
- CA
- Canada
- Prior art keywords
- dose
- nanoparticles
- component
- bioactive agent
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
Abstract
The invention discloses the nanoparticles composed of chitosan, poly-.gamma.-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery.
Claims (44)
1. A dose of nanoparticles to a patient characterized by enhancing intestinal paracellular transport or brain blood paracellular transport, each nanoparticle comprising a first component of at least one bioactive agent, a second component that is negatively charged, and a third component of low molecular weight chitosan, wherein said first and second components occupy a center core and said third component dominates on a surface of said nanoparticle.
2. The dose of claim 1, wherein said second component is .gamma.-PGA.
3. The dose of claim 2, wherein a weight ratio of said chitosan to .gamma.-PGA
in nanoparticles is 0.75 to 0.167 or higher.
in nanoparticles is 0.75 to 0.167 or higher.
4. The dose of claim 1, wherein said first component is insulin.
5. The dose of claim 1, wherein said first component is insulin and said second component is .gamma.-PGA, wherein a weight ratio of the three components is about 0.083:0.167:0.75.
6. The dose of claim 1, wherein said first component is insulin, wherein an insulin loading capacity is at least 8 w/w% of the nanoparticles.
7. The dose of claim 1, wherein said first component is insulin, wherein an insulin loading capacity is at least 14 w/w% of the nanoparticles.
8. The dose of claim 1, wherein a zeta potential of the nanoparticles is between about 15 and 40 mV.
9. The dose of claim 1, wherein a zeta potential of the nanoparticles is between about 25 to 40 mV.
10. The dose of claim 1, wherein said second component is heparin or alginate.
11. The dose of claim 1, wherein the at least one bioactive agent is an antagonist for Alzheimer's disease.
12. The dose of claim 1, wherein the at least one bioactive agent is for treating Alzheimer's disease selected from a group consisting of memantine hydrochloride, donepezil hydrochloride, rivastigmine tartrate, galantamine hydrochloride, and tacrine hydrochloride.
13. The dose of claim 1, wherein the at least one bioactive agent is insulin or insulin analog.
14. The dose of claim 1, wherein the at least one bioactive agent is selected from a group consisting of proteins, peptides, nucleosides, nucleotides, antiviral agents, antineoplastic agents, antibiotics, and anti-inflammatory drugs.
15. The dose of claim 1, wherein the at least one bioactive agent is an antagonist for Parkison's disease.
16. The dose of claim 1, wherein the at least one bioactive agent is selected from a group consisting of epidermal growth factor (EGF), insulin-like growth factor (IGF), transforming growth factor (TGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), bone morphogenic protein (BMP), and fibroblast growth factor.
17. The dose of claim 1, wherein the at least one bioactive agent is selected from a group consisting ofoxytocin, vasopressin, adrenocorticotrophic hormone, prolactin, luliberin or luteinising hormone releasing hormone, growth hormone, growth hormone releasing factor, somatostatin, glucagon, interferon, gastrin, tetragastrin, pentagastrin, urogastroine, secretin, calcitonin, enkephalins, endorphins, angiotensins, renin, bradykinin, bacitracins, polymixins, colistins, tyrocidin, gramicidines, monoclonal antibodies and soluble vaccines.
18. The dose of claim 1, wherein the at least one bioactive agent comprises stem cells.
19. The dose of claim 1, wherein said nanoparticles are further encapsulated in a gelcap capsule.
20. The dose of claim 19, wherein a surface of said gelcap capsule comprises glycerin.
21. The dose of claim 20, wherein a surface of said gelcap capsule is hydrophilic.
22. The dose of claim 1, wherein the third component is crosslinked.
23. The dose of claim 22, wherein the third component is crosslinked at a degree of crosslinking less than 50%.
24. The dose of claim 22, wherein the third component is crosslinked with a crosslinking agent selected from a group consisting of genipin, its derivatives, analog, stereoisomers and mixtures thereof.
25. The dose of claim 1, wherein the low molecule weight chitosan has a molecular weight of 80 kDa or less.
26. The dose of claim 1, wherein the low molecule weight chitosan is further grafted with a polymer having a chemical formula as:
where R is >= 12
where R is >= 12
27. The dose of claim 1, wherein the low molecular weight chitosan has a molecular weight of less than about 40 kDa.
28. The dose of claim 1, wherein the nanoparticles have a mean particle size between about 100 and 300 nanometers.
29. The dose of claim 1, wherein the nanoparticles are formed via a simple and mild ionic-gelation method.
30. A method of enhancing intestinal paracellular transport or brain blood paracellular transport comprising administering a dose of nanoparticles, wherein each nanoparticle comprises a first component of at least one bioactive agent, a second component that is negatively charged, and a third component of low molecular weight chitosan, wherein said third component dominates on a surface of said nanoparticle.
31. The method of claim 30, wherein the step of administering said dose of nanoparticles is via oral administration for enhancing the intestinal paracellular transport.
32. The method of claim 30, wherein the step of administering said dose of nanoparticles is via blood vessel administration for enhancing the brain blood paracellular transport.
33. An oral dose of nanoparticles that enhance intestinal paracellular transport or blood brain paracellular transport comprising .gamma.-PGA and low molecular weight chitosan, wherein said chitosan dominates on a surface of said nanoparticles.
34. The oral dose of claim 33, wherein a weight ratio of said chitosan to .gamma.-PGA is 0.75 to 0.167 or higher.
35. The oral dose of claim 33, wherein said nanoparticles further comprise at least one bioactive agent.
36. The oral dose of claim 35, wherein the bioactive agent is an Alzheimer antagonist.
37. The oral dose of claim 35, wherein the bioactive agent is selected from a group consisting of proteins, peptides, nucleosides, nucleotides, antiviral agents, antineoplastic agents, antibiotics, and anti-inflammatory drugs.
38. The oral dose of claim 33, wherein said .gamma.-PGA is characterized with a negative charge.
39. The oral dose of claim 33, wherein the surface of said nanoparticles is characterized with a positive surface charge.
40. The oral dose of claim 33, wherein a zeta potential of the nanoparticles is between about 15 and 40 mV.
41. The oral dose of claim 33, wherein a zeta potential of the nanoparticles is between about 25 to 40 mV.
42. The oral dose of claim 33, wherein said nanoparticles are further encapsulated in a gelcap capsule.
43. The oral dose of claim 42, wherein a surface of said gelcap capsule comprises glycerin.
44. The oral dose of claim 42, wherein a surface of said gelcap capsule is hydrophilic.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/029,082 US7265090B2 (en) | 2004-10-05 | 2005-01-04 | Nanoparticles for paracellular drug delivery |
US11/029,082 | 2005-01-04 | ||
US11/284,734 US7282194B2 (en) | 2004-10-05 | 2005-11-21 | Nanoparticles for protein drug delivery |
US11/284,734 | 2005-11-21 | ||
PCT/US2005/047125 WO2006073950A2 (en) | 2005-01-04 | 2005-12-27 | Nanoparticles for protein drug delivery |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2592991A1 true CA2592991A1 (en) | 2006-07-13 |
CA2592991C CA2592991C (en) | 2012-09-11 |
Family
ID=36648027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2592991A Expired - Fee Related CA2592991C (en) | 2005-01-04 | 2005-12-27 | Nanoparticles for protein drug delivery |
Country Status (9)
Country | Link |
---|---|
US (4) | US7282194B2 (en) |
EP (1) | EP1833470A4 (en) |
JP (2) | JP5384831B2 (en) |
CN (1) | CN101360486B (en) |
AU (1) | AU2005322940B2 (en) |
BR (1) | BRPI0518093A (en) |
CA (1) | CA2592991C (en) |
HK (1) | HK1122508A1 (en) |
WO (1) | WO2006073950A2 (en) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7901711B1 (en) * | 2006-04-17 | 2011-03-08 | Gp Medical, Inc. | Nanoparticles for protein/peptide delivery and delivery means thereof |
US7282194B2 (en) * | 2004-10-05 | 2007-10-16 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
US8137697B1 (en) * | 2004-10-05 | 2012-03-20 | Gp Medical, Inc. | Nanoparticles for protein/peptide delivery and delivery means thereof |
US7879361B2 (en) * | 2005-01-04 | 2011-02-01 | Gp Medical, Inc. | Nanoparticles for drug delivery |
US7541028B2 (en) * | 2005-01-04 | 2009-06-02 | Gp Medical, Inc. | Nanoparticles for monoclonal antibody delivery |
EP1774971A1 (en) * | 2005-10-14 | 2007-04-18 | Advanced in Vitro Cell Technologies, S.L. | Chitosan and heparin nanoparticles |
US8968721B2 (en) | 2005-12-28 | 2015-03-03 | Advanced Bionutrition Corporation | Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same |
ES2470340T3 (en) | 2005-12-28 | 2014-06-23 | Advanced Bionutrition Corporation | Administration vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in vitreous form |
EP1991111B1 (en) * | 2006-02-27 | 2011-04-06 | Edwards Lifesciences Corporation | Hydrogel for an intravenous amperometric biosensor |
JP2007291324A (en) * | 2006-03-31 | 2007-11-08 | Jsr Corp | Oxide particulate-containing polysiloxane composition and its production process |
JP2007270056A (en) * | 2006-03-31 | 2007-10-18 | Jsr Corp | Metal oxide particulate-containing polysiloxane composition and method for producing the same |
US8449915B1 (en) * | 2006-04-17 | 2013-05-28 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
BRPI0713533A2 (en) * | 2006-06-26 | 2012-04-17 | Mutual Pharmaceutical Co | active agent formulations, manufacturing methods, and methods of use |
US20080160096A1 (en) * | 2006-07-27 | 2008-07-03 | Janos Berbely | Polymeric nanoparticles by ion-ion interactions |
CN101148511B (en) * | 2006-09-18 | 2010-10-20 | 中国科学院过程工程研究所 | Method for preparing fluorescent chitosan micro-sphere and application of the same in tracer field |
US8946200B2 (en) * | 2006-11-02 | 2015-02-03 | Southwest Research Institute | Pharmaceutically active nanosuspensions |
WO2008076975A1 (en) | 2006-12-18 | 2008-06-26 | Advanced Bionutrition Corporation | A dry food product containing live probiotic |
US20080193547A1 (en) * | 2006-12-27 | 2008-08-14 | Janos Borbely | Polymeric nanoparticles by ion-ion Interactions |
US8197828B2 (en) * | 2007-05-09 | 2012-06-12 | Nitto Denko Corporation | Compositions that include a hydrophobic compound and a polyamino acid conjugate |
WO2009035438A1 (en) * | 2007-09-13 | 2009-03-19 | Janos Borbely | Polymeric nanoparticles by ion-ion interactions |
WO2009065181A1 (en) * | 2007-11-21 | 2009-05-28 | Apollo Life Sciences Limited | Nanostructures suitable for delivery of agents |
IL188647A0 (en) | 2008-01-08 | 2008-11-03 | Orina Gribova | Adaptable structured drug and supplements administration system (for oral and/or transdermal applications) |
US8404850B2 (en) * | 2008-03-13 | 2013-03-26 | Southwest Research Institute | Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors |
CA2722145A1 (en) * | 2008-04-24 | 2009-10-29 | Medtronic, Inc. | Rehydratable thiolated polysaccharide particles and sponge |
AU2009240513B2 (en) * | 2008-04-24 | 2015-03-26 | Medtronic, Inc. | Chitosan-containing protective composition |
US8653319B2 (en) | 2008-04-24 | 2014-02-18 | Medtronic, Inc. | Cold ionizing radiation sterilization |
EP2313104B2 (en) * | 2008-04-24 | 2020-08-26 | Medtronic, Inc | Thiolated chitosan gel |
JP5833919B2 (en) | 2008-04-24 | 2015-12-16 | メドトロニック,インコーポレイテッド | Protective gel based on chitosan and oxidized polysaccharide |
KR20110028631A (en) * | 2008-07-01 | 2011-03-21 | 닛토덴코 가부시키가이샤 | Pharmaceutical composition containing surface-coated microparticles |
US8722706B2 (en) * | 2008-08-15 | 2014-05-13 | Southwest Research Institute | Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts |
US20100104608A1 (en) * | 2008-09-26 | 2010-04-29 | Tyco Healthcare Group Lp | Reactive surgical implant |
US8241654B2 (en) * | 2008-09-26 | 2012-08-14 | Tyco Healthcare Group Lp | Reactive surgical implant |
US8309134B2 (en) * | 2008-10-03 | 2012-11-13 | Southwest Research Institute | Modified calcium phosphate nanoparticle formation |
US20100111919A1 (en) * | 2008-10-31 | 2010-05-06 | Tyco Healthcare Group Lp | Delayed gelation compositions and methods of use |
JP2010132609A (en) * | 2008-12-05 | 2010-06-17 | Fujifilm Corp | Casein nanoparticle |
US20100159010A1 (en) * | 2008-12-24 | 2010-06-24 | Mutual Pharmaceutical Company, Inc. | Active Agent Formulations, Methods of Making, and Methods of Use |
WO2010087781A1 (en) * | 2009-01-28 | 2010-08-05 | Agency For Science, Technology And Research | Polyelectrolyte complexes with bound peptides |
CA2986751A1 (en) | 2009-03-27 | 2010-09-30 | Intervet International B.V. | Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish |
NZ597053A (en) | 2009-05-26 | 2014-02-28 | Advanced Bionutrition Corp | Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making |
US8404281B2 (en) | 2009-06-08 | 2013-03-26 | Avant Garde Therapeutics & Technologies Llc | Formulations |
KR101342641B1 (en) | 2009-06-25 | 2013-12-20 | 주식회사 바이오리더스 | Composition for Adjuvant Comprising Poly-Gamma-Glutamic Acid-Chitosan Nanoparticle |
BR112012000379A2 (en) | 2009-07-09 | 2016-03-29 | Oshadi Drug Administration Ltd | carrier matrix compositions, methods and uses |
US8637096B2 (en) | 2009-12-04 | 2014-01-28 | Curtis C. Stojan | Compositions and method for enhancing insulin activity |
US9504750B2 (en) | 2010-01-28 | 2016-11-29 | Advanced Bionutrition Corporation | Stabilizing composition for biological materials |
RU2535869C2 (en) | 2010-01-28 | 2014-12-20 | Эдванст Бионутришн Корпорейшн | Dry glass-like composition for stabilisation and protection of biologically active material, and method for its obtaining |
US9028873B2 (en) * | 2010-02-08 | 2015-05-12 | Southwest Research Institute | Nanoparticles for drug delivery to the central nervous system |
WO2011100460A2 (en) * | 2010-02-11 | 2011-08-18 | Ecole Polytechnique Federale De Lausanne | Ccr7 ligand delivery and co-delivery in immunotherapy |
JP2011178764A (en) * | 2010-03-04 | 2011-09-15 | Ajinomoto Co Inc | Intestinal bifidobacterium proliferation promoter and intestinal barrier function-improving agent |
EP2417968A1 (en) | 2010-07-29 | 2012-02-15 | Consorzio per il Centro di Biomedicina Molecolare Scrl | Particle comprising cytokines, antibodies and polymers and use thereof as medicament for the treatment of cancer |
AU2011289272B2 (en) | 2010-08-13 | 2015-02-05 | Advanced Bionutrition Corporation | Dry storage stabilizing composition for biological materials |
AU2011336352B2 (en) | 2010-12-02 | 2015-05-28 | Greenmark Biomedical Inc. | Aptamer bioconjugate drug delivery device |
US9713702B2 (en) * | 2011-03-14 | 2017-07-25 | The Board Of Trustee Of The Leland Stanford Junior University | Methods of electric field induced delivery of compounds, compositions used in delivery, and systems of delivery |
WO2012170017A1 (en) * | 2011-06-08 | 2012-12-13 | Avant Garde Therapeutics Inc. | Novel formulations |
CA2869821C (en) | 2011-06-13 | 2018-06-19 | Rival, Societe En Commandite | N,n,n-trialkylaminopolymers, methods of their preparation and uses thereof |
JP5801626B2 (en) * | 2011-06-30 | 2015-10-28 | 国立大学法人信州大学 | Method for producing composite nanofiber |
AU2012318273B2 (en) * | 2011-12-02 | 2016-05-19 | Greenmark Biomedical Inc. | Aptamer bioconjugate drug delivery device |
US8883717B2 (en) * | 2012-03-30 | 2014-11-11 | Artificial Cell Technologies, Inc. | Antigenic compositions and methods |
WO2013166487A1 (en) | 2012-05-04 | 2013-11-07 | Yale University | Highly penetrative nanocarriers for treatment of cns disease |
US8313774B1 (en) | 2012-06-26 | 2012-11-20 | Magnifica Inc. | Oral solid composition |
US11504422B2 (en) | 2013-01-09 | 2022-11-22 | National Cheng Kung University | Biodegradable nanocomplex |
TWI511744B (en) * | 2013-01-09 | 2015-12-11 | Univ Nat Cheng Kung | Biodegradable carrier with arbitrarily adjustable interface charges and particle sizes, a preparing method and a pharmaceutical composition of the same |
WO2015032971A1 (en) * | 2013-09-09 | 2015-03-12 | Lek Pharmaceuticals D.D. | Polymer selection for preparation of nps with high protein loading |
US20160243056A1 (en) | 2013-10-01 | 2016-08-25 | Manju Ray | Sustained Release Formulations Containing Methylglyoxal and Their Therapeutic Applications |
US20160271271A1 (en) * | 2013-11-05 | 2016-09-22 | Elena Molokanova | Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels |
CN103656623B (en) * | 2013-12-06 | 2015-04-15 | 南通大学 | Nanoparticles loaded with neurotrophic factors, and preparation and applications thereof |
US11039621B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
US11039620B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
US9622483B2 (en) | 2014-02-19 | 2017-04-18 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
WO2016065279A1 (en) * | 2014-10-23 | 2016-04-28 | Symbiotic Health Inc. | A capsule for the oral administration of biopharmaceuticals |
AU2016257813B2 (en) | 2015-05-01 | 2021-05-13 | Rani Therapeutics, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
PT3328215T (en) | 2015-07-29 | 2021-08-03 | Advanced Bionutrition Corp | Stable dry probiotic compositions for special dietary uses |
KR101882820B1 (en) | 2015-12-30 | 2018-07-30 | 주식회사 삼양바이오팜 | Mucoadhesive pharmaceutical composition and preparation method thereof |
US11491114B2 (en) | 2016-10-12 | 2022-11-08 | Curioralrx, Llc | Formulations for enteric delivery of therapeutic agents |
US20230190665A1 (en) * | 2017-01-19 | 2023-06-22 | The Johns Hopkins University | Therapeutic protein-loaded nanoparticle and method for preparing the same |
CN107651664B (en) * | 2017-10-16 | 2020-11-06 | 浙江领蔚生物技术有限公司 | Fluorescent carbon nano-particle and application thereof as cell marking material |
JP2021519310A (en) | 2018-03-28 | 2021-08-10 | グリーンマーク バイオメディカル インコーポレイテッドGreenMark Biomedical, Inc. | Phosphate cross-linked starch nanoparticles and dental treatment |
WO2023286049A1 (en) | 2021-07-12 | 2023-01-19 | Zidkiyahu Simenhaus | Protein containing bio-active compositions comprising cellulose microparticle carriers |
CN114470186B (en) * | 2022-02-17 | 2023-10-20 | 唐颐控股(深圳)有限公司 | Preparation method of inhalable nanometer new crown vaccine |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6268894A (en) | 1993-02-22 | 1994-09-14 | Alza Corporation | Compositions for oral delivery of active agents |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
US5962019A (en) | 1995-08-25 | 1999-10-05 | Sangstat Medical Corporation | Oral cyclosporin formulations |
KR20000067855A (en) * | 1996-07-10 | 2000-11-25 | 웨스트 파머슈티컬 서비스 드러그 딜리버리 앤드 크리니컬 리써치 센터 리미티드 | Gene therapy delivery system for targeting to endothelia |
US6933331B2 (en) | 1998-05-22 | 2005-08-23 | Nanoproducts Corporation | Nanotechnology for drug delivery, contrast agents and biomedical implants |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
IE970794A1 (en) | 1997-09-24 | 2000-08-23 | Elan Corp Plc | Composition and method for enhancing paracellular transport across cell layers |
EP1021168A4 (en) * | 1997-10-09 | 2006-08-30 | Univ Vanderbilt | Micro-particulate and nano-particulate polymeric delivery system |
US6726934B1 (en) | 1997-10-09 | 2004-04-27 | Vanderbilt University | Micro-particulate and nano-particulate polymeric delivery system |
US6517869B1 (en) | 1997-12-12 | 2003-02-11 | Expression Genetics, Inc. | Positively charged poly(alpha-(omega-aminoalkyl)lycolic acid) for the delivery of a bioactive agent via tissue and cellular uptake |
FR2780901B1 (en) | 1998-07-09 | 2000-09-29 | Coletica | PARTICLES, IN PARTICULAR MICRO- OR NANOPARTICLES OF CROSSLINKED MONOSACCHARIDES AND OLIGOSACCHARIDES, THEIR PREPARATION METHODS AND COSMETIC, PHARMACEUTICAL OR FOOD COMPOSITIONS CONTAINING THE SAME |
US6632457B1 (en) | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
AU4476600A (en) * | 1999-04-22 | 2000-11-10 | Vanderbilt University | Polymeric encapsulation system promoting angiogenesis |
AU4563100A (en) | 1999-05-07 | 2000-11-21 | Pharmasol Gmbh | Medicament vehicle for the controlled administration of an active agent, produced from lipid matrix-medicament conjugates |
WO2001001964A2 (en) * | 1999-06-23 | 2001-01-11 | Sedum Laboratories, Inc. | Ionically formulated biomolecule microcarriers |
CN1379687A (en) * | 1999-09-14 | 2002-11-13 | 生物医学阿佩则系统有限公司 | Magnetic nanoparticles having biochemial activity, method for production thereof and their use |
GB0126923D0 (en) | 2001-11-09 | 2002-01-02 | Procter & Gamble | Chitosan compositions |
AU2002359855B2 (en) * | 2001-12-21 | 2008-08-21 | David S. Soane | Use of oligomers and polymers for drug solublization, stabilization, and delivery |
GB0302738D0 (en) * | 2003-02-06 | 2003-03-12 | Advanced Biopolymers As | Composition |
ES2226567B1 (en) * | 2003-06-20 | 2006-07-01 | Universidad De Santiago De Compostela | NANOPARTICULAS OF HIALURONIC ACID. |
US7282194B2 (en) * | 2004-10-05 | 2007-10-16 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
US7265090B2 (en) * | 2004-10-05 | 2007-09-04 | Gp Medical, Inc. | Nanoparticles for paracellular drug delivery |
US7611690B2 (en) * | 2005-01-04 | 2009-11-03 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
US7541046B1 (en) * | 2005-01-04 | 2009-06-02 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
US7541028B2 (en) * | 2005-01-04 | 2009-06-02 | Gp Medical, Inc. | Nanoparticles for monoclonal antibody delivery |
US7291598B2 (en) * | 2005-01-04 | 2007-11-06 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
US7879819B1 (en) * | 2005-01-04 | 2011-02-01 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
US7604795B1 (en) * | 2005-01-04 | 2009-10-20 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
US20070148251A1 (en) * | 2005-12-22 | 2007-06-28 | Hossainy Syed F A | Nanoparticle releasing medical devices |
-
2005
- 2005-11-21 US US11/284,734 patent/US7282194B2/en not_active Expired - Fee Related
- 2005-12-27 CN CN2005800449397A patent/CN101360486B/en not_active Expired - Fee Related
- 2005-12-27 CA CA2592991A patent/CA2592991C/en not_active Expired - Fee Related
- 2005-12-27 JP JP2007549559A patent/JP5384831B2/en not_active Expired - Fee Related
- 2005-12-27 WO PCT/US2005/047125 patent/WO2006073950A2/en active Application Filing
- 2005-12-27 BR BRPI0518093-7A patent/BRPI0518093A/en not_active IP Right Cessation
- 2005-12-27 EP EP05857226A patent/EP1833470A4/en not_active Withdrawn
- 2005-12-27 AU AU2005322940A patent/AU2005322940B2/en not_active Ceased
-
2007
- 2007-07-26 US US11/881,217 patent/US7803748B2/en not_active Expired - Fee Related
-
2008
- 2008-04-24 US US12/150,027 patent/US7455830B2/en not_active Expired - Fee Related
-
2009
- 2009-03-30 HK HK09102982.7A patent/HK1122508A1/en not_active IP Right Cessation
-
2010
- 2010-08-27 US US12/807,084 patent/US8454966B2/en not_active Expired - Fee Related
-
2013
- 2013-05-29 JP JP2013112996A patent/JP2013177434A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BRPI0518093A (en) | 2008-10-28 |
US20080233200A1 (en) | 2008-09-25 |
JP2013177434A (en) | 2013-09-09 |
WO2006073950A2 (en) | 2006-07-13 |
WO2006073950A3 (en) | 2008-10-30 |
US7282194B2 (en) | 2007-10-16 |
AU2005322940B2 (en) | 2010-07-08 |
JP5384831B2 (en) | 2014-01-08 |
AU2005322940A1 (en) | 2006-07-13 |
US8454966B2 (en) | 2013-06-04 |
CA2592991C (en) | 2012-09-11 |
JP2008528446A (en) | 2008-07-31 |
CN101360486A (en) | 2009-02-04 |
US20100330167A1 (en) | 2010-12-30 |
EP1833470A2 (en) | 2007-09-19 |
US7455830B2 (en) | 2008-11-25 |
US20060147539A1 (en) | 2006-07-06 |
CN101360486B (en) | 2012-09-05 |
US7803748B2 (en) | 2010-09-28 |
EP1833470A4 (en) | 2012-08-22 |
US20080213354A1 (en) | 2008-09-04 |
WO2006073950B1 (en) | 2008-12-11 |
HK1122508A1 (en) | 2009-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2592991A1 (en) | Nanoparticles for protein drug delivery | |
Bernkop-Schnürch et al. | Thiomers: preparation and in vitro evaluation of a mucoadhesive nanoparticulate drug delivery system | |
Wong et al. | Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment | |
Vauthier et al. | Design aspects of poly (alkylcyanoacrylate) nanoparticles for drug delivery | |
US7381716B2 (en) | Nanoparticles for protein drug delivery | |
US8187570B1 (en) | Nanoparticles for protein drug delivery | |
US7556826B2 (en) | Nanoparticles for protein drug delivery | |
US20070116772A1 (en) | Nanoparticles for protein drug delivery | |
US7858596B2 (en) | Nanoparticles for protein drug delivery | |
JP2008528446A5 (en) | ||
WO2011133198A1 (en) | A pharmaceutical composition of nanoparticles | |
US7611690B2 (en) | Nanoparticles for protein drug delivery | |
US20070237831A1 (en) | Nanoparticles for monoclonal antibody delivery | |
Jin et al. | Chitosan–glutathione conjugate-coated poly (butyl cyanoacrylate) nanoparticles: promising carriers for oral thymopentin delivery | |
US8791069B1 (en) | Pharmaceutical composition of nanoparticles | |
CN102908627A (en) | pH-sensitive nanoparticles for oral insulin delivery | |
US8226928B1 (en) | Pharmaceutical composition of nanoparticles | |
US7993624B2 (en) | Nanoparticles for protein drug delivery | |
US8153153B1 (en) | Pharmaceutical composition of nanoparticles for protein drug delivery | |
Srivastava et al. | Development and evaluation of stavudine loaded injectable polymeric particulate systems | |
Silva et al. | Novel chitosan-based strategies for insulin nanoencapsulation | |
Hussein et al. | Polymeric micro and nanoparticles as promising drug delivery vehicles: a review | |
Shah et al. | Nanoparticulate Drug Delivery System: Dynamic Platform for Protein and Peptide Molecules | |
WO2008141496A1 (en) | Sustained-release system for epo and gm-csf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20171227 |